A recent quality control inspection conducted by the Central Drugs Standard Control Organization (CDSCO) has unveiled disturbing revelations about the safety and efficacy of 53 medications. Shockingly, widely used drugs such as Paracetamol and Pan D have failed the tests, raising serious concerns. The CDSCO’s stringent assessments are crucial in upholding pharmaceutical quality and safety standards, and the latest report has identified several drugs as “not of standard quality” (NSQ), failing to meet the required norms. These include Paracetamol IP 500 mg, Vitamin B complex, Telmisartan, Shelcal Vitamin C and D3, Vitamin B complex and Vitamin C soft gels, Rifmin 550, Nimesulide with Paracetamol and Chlozoxazone tablets, Ciprofloxacin Tablets I.P 500 mg, Amoxicillin & Potassium Clavulanate Tablets (Mexclav 625), and Metformin Hydrochloride Sustained Release Tablets IP (Glycimet-SR-500), among others. Furthermore, a drug testing laboratory in Kolkata has flagged Alkem Health Science’s antibiotics, Pan D and Clavam 625, as “spurious.” Additionally, the same lab has reported that Cepodem XP 50 Dry Suspension, manufactured by Hetero in Hyderabad and used to treat bacterial infections in children, has been declared substandard. These findings highlight the need for urgent action to ensure the safety and efficacy of pharmaceutical products.
